BICO Group Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

BICO Group şirketinin kazançları yıllık ortalama -73.8% oranında azalırken, Life Sciences sektörünün kazançları yıllık 11.7% oranında artan oldu. Gelirler yıllık ortalama 44.9% oranında artan oldu.

Anahtar bilgiler

-73.8%

Kazanç büyüme oranı

-68.9%

EPS büyüme oranı

Life Sciences Sektör Büyümesi	21.5%
Gelir büyüme oranı	44.9%
Özkaynak getirisi	-50.5%
Net Marj	-61.8%
Sonraki Kazanç Güncellemesi	26 Nov 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Gelir ve Gider Dağılımı

BICO Group nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

OTCPK:CLLK.F Gelir, gider ve kazançlar (SEK Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Jun 24	2,423	-1,498	1,532	116
31 Mar 24	2,426	-1,649	1,554	101
31 Dec 23	2,405	-1,697	1,537	0
30 Sep 23	2,252	-527	1,270	143
30 Jun 23	2,256	-390	1,380	143
31 Mar 23	2,297	-117	1,645	67
31 Dec 22	2,327	-85	1,818	0
30 Sep 22	2,278	41	1,857	0
30 Jun 22	1,995	-130	1,666	0
31 Mar 22	1,743	-224	1,354	0
31 Dec 21	1,378	-228	1,061	0
30 Sep 21	993	-188	749	0
30 Jun 21	744	-96	519	0
31 Mar 21	460	-50	342	0
31 Dec 20	369	-36	273	0
31 Aug 20	236	-62	218	0
31 May 20	213	-49	197	0
29 Feb 20	197	-24	176	0
30 Nov 19	173	-5	138	0
31 Aug 19	135	1	106	0
31 May 19	118	3	87	0
28 Feb 19	97	4	69	0
30 Nov 18	76	2	55	0
31 Aug 18	61	1	43	0
31 May 18	45	1	30	0
28 Feb 18	34	-2	24	0
30 Nov 17	27	-2	21	0
31 Aug 17	20	-1	16	0
31 Aug 16	6	-1	4	0

Kaliteli Kazançlar: CLLK.F şu anda kârlı değil.

Büyüyen Kar Marjı: CLLK.F şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: CLLK.F kârlı değildir ve zararlar son 5 yılda yılda 73.8% oranında artmıştır.

Büyüme Hızlandırma: CLLK.F 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: CLLK.F kârlı olmadığından, geçmiş yıl kazanç büyümesinin Life Sciences sektörüyle ( -4.7% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: CLLK.F hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -50.48% ) sahiptir.

BICO Group Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

BICO Group AB (publ) to Report Fiscal Year 2024 Final Results on Mar 20, 2025

BICO Group AB (publ) to Report Fiscal Year 2024 Results on Feb 19, 2025

BICO Group AB (publ) to Report Q3, 2024 Results on Nov 13, 2024

BICO Group AB (publ) to Report Fiscal Year 2023 Results on Mar 15, 2024

BICO Group AB (publ) to Report Fiscal Year 2023 Results on Feb 20, 2024

BICO Group AB (publ) to Report Q1, 2023 Results on May 04, 2023

Recent updates

BICO Group AB (publ) to Report Fiscal Year 2024 Final Results on Mar 20, 2025

BICO Group AB (publ), Annual General Meeting, May 08, 2025

BICO Group AB Announces Management Changes

BICO Group AB (publ) Elects Alexandra Gatzemeyer as Member of the Board of Directors

BICO Group AB (publ) Announces the Appointment of Anders Fogelberg as Chief Commercial Officer, Effective June 13, 2024

BICO Group AB (publ) Announces Gerry Mackay and Erik Gatenholm Decline Re-Election of the Board of Directors

BICO Group AB (publ) to Report Fiscal Year 2024 Results on Feb 19, 2025

BICO Group AB (publ) to Report Q3, 2024 Results on Nov 13, 2024

BICO Group AB (publ) Appoints Catharina Nordlund as Global Head of HR

BICO Group AB (publ) to Report Fiscal Year 2023 Results on Mar 15, 2024

BICO Group AB (publ) Announces Chief Executive Officer Changes

Beos Light Industrial Germany 1 Fund, a fund managed by BEOS AG agreed to acquire property on Wagner-Régeny-Straße 15 from BICO Group AB (publ) (OM:BICO) for €21 million.

BICO Group AB (publ) Elects Gerry Mackay to Its Board of Directors

BICO Group AB (publ) to Report Fiscal Year 2023 Results on Feb 20, 2024

BICO Group AB Appoints Marius Balger as Chief Operating Officer, Effective March 1, 2023

BICO Group AB Announces the Appointment of Jacob Thordenberg as Group CFO

BICO Group AB (publ) to Report Q1, 2023 Results on May 04, 2023

BICO Group AB (publ) to Report Q2, 2023 Results on Jul 20, 2023

BICO Group Announces Appointment of Nomination Committee 2023

BICO Group AB (publ) to Report Fiscal Year 2023 Results on Feb 22, 2023

BICO Group Adds Åsa Hillsten as SVP and Head of IR

BICO Group AB (publ) (OM : BICO) acquired Allegro 3D for $11 million.

BICO (publ) Appoints Mikael Engblom as Interim CFO

BICO Group AB (Publ) Announces Board Appointments

BICO Reaches Beneficial and Sustainable Solution with Organovo

DISPENDIX, A BICO Company, Announces That the I.DOT HT Non-contact Dispenser and the L.DROP Liquid Handler will be introduced at SLAS 2022

BICO Group AB Announces Statement Regarding Counterclaims in Patent Lawsuit by Organovo Against Cellink

BICO Group AB (publ) (OM:BICO) agreed to acquire Biosero Llc.

BICO Group AB (publ) (OM:BICO) acquired all outstanding shares in Advanced BioMatrix, Inc. for $18 million.

CELLINK Receives Patent for Robotic Systems for Personalized and Automated Aesthetic Medical Procedures

Cellink AB (publ) (OM:CLNK B) completed the acquisition of Discover Echo Inc.

Cellink AB (publ) (OM:CLNK B) completed the acquisition of Nanoscribe GmbH for approximately €37 million.

Cellink AB (publ) (OM:CLNK B) entered into an agreement to acquire Nanoscribe GmbH for €34 million.

Cellink AB (publ) (OM:CLNK B) entered into an agreement to acquire MatTek Corporation for $68 million.

Cellink AB (publ) (OM:CLNK B) completed the acquisition of Ginolis Ltd from Verso Fund II of Verso Capital Oy, Finnvera plc and Innovestor Ventures for €65.7 million.

Cellink AB (publ) to Report Fiscal Year 2021 Results on Mar 16, 2022

Cellink AB (publ) (OM:CLNK B) entered into an agreement to acquire Ginolis Ltd for €70 million.

Cellink AB (publ) Announces Distribution Agreement Including New Products for Single-Cell RNA Sequencing and NGS Library Preparation

Cellink Announces Third Year Extension of Collaboration with A Global Biopharmaceutical Company for Drug Discovery

Cellink and Phasefocus Announces a Partnership to Bring Livecyte High Content Live Cell Imager to a Wider Audience

Cellink AB (publ) Elects Aristotelis Nastos as Member of the Board of Directors

CELLINK and Atelerix Team Up to Enable the Shipping At Room Temperature of Fragile 3D Bioprinted Constructs by the World's Bioprinting Community

CELLINK to Help Develop 3D Bioprinted Personalised Scaffolds for Tissue Regeneration of Ankle Joint S as Part of the Triankle Project

Cellink AB (publ) to Report Second Half, 2020 Results on Oct 22, 2020

Cellink AB (Publ) Announces Leaving Board of Directors for an Operational Role as Business Area Manager for the Bioprinting Business Unit

Cellink AB (publ) (OM:CLNK B) completed the acquisition of SCIENION AG from NRW.Bank Venture Fonds, L.P., managed by NRW.Bank, Investment Arm and other shareholders.

Cellink AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 945.99632 million.

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin